1	Misalignment between circadian preference and accelerometer-derived actual sleep-
2	wake cycle is associated with increased risk of cardiometabolic diseases: a prospective
3	cohort study in UK Biobank
4	Yue Chen <sup>1</sup> , MSc; Tingting Geng <sup>2</sup> , MD, PhD; Xinming Xu <sup>1</sup> , B.S.; Zhicheng Zhang <sup>1</sup> , MSc;
5	Lili Huang <sup>1</sup> , PhD; Haiyang Dong <sup>1</sup> , B.S.; Huan Yu <sup>4,5,6</sup> , MD, PhD; Xiang Gao <sup>1</sup> *, MD, PhD;
6	Liang Sun <sup>1</sup> *, MD, PhD;
7	
8	<sup>1</sup> Department of Nutrition and Food Hygiene, School of Public Health, Institute of Nutrition,
9	Clinical Research Unit, Institute of Clinical Medicine, Zhongshan Hospital, Fudan
10	University, Shanghai, China
11	<sup>2</sup> Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of
12	Environment and Health, School of Public Health, Tongji Medical College, Huazhong
13	University of Science and Technology, Wuhan, Hubei Province, China
14	<sup>3</sup> Sleep and Wake Disorders Center of Fudan University, Shanghai, China
15	<sup>4</sup> Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
16	<sup>5</sup> National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai,
17	China
18	
19	* Corresponding authors:
20	Liang Sun, MD, PhD

<sup>21</sup> Department of Nutrition and Food Hygiene, School of Public Health, Institute of Nutrition,

<sup>22</sup> Clinical Research Unit, Institute of Clinical Medicine, Zhongshan Hospital, Fudan NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 23 University, 130 Dongan Rd, Shanghai 200032, China; Email: sun liang@fudan.edu.cn
- 24 Xiang Gao, MD, PhD
- 25 Department of Nutrition and Food Hygiene, School of Public Health, Institute of Nutrition,
- 26 Clinical Research Unit, Institute of Clinical Medicine, Zhongshan Hospital, Fudan
- 27 University, 130 Dongan Rd, Shanghai 200032, China; Email: <u>xiang\_gao@fudan.edu.cn</u>

28

- 30 Short title: circadian misalignment and cardiometabolic diseases
- 31 Word count: 8436 (including Title Page, Abstract, Text, References, Tables and Figures
- 32 Legends)

# 33 Abstract (349 words)

**Background:** Evidence has linked several circadian disruption indicators, such as social jetlag and shift work, to adverse health outcomes, however, associations of misalignment between circadian preference and actual sleep-wake cycle with cardiometabolic diseases (CMDs) remains unclear. We aimed to prospectively investigate the associations of the circadian misalignment with CMDs including type 2 diabetes (T2D), chronic heart diseases (CHD), and stroke, and to uncover potential mechanisms linking circadian misalignment and CMDs.

Methods: A total of 60,965 participants from the UK Biobank study without baseline CMDs 41 and followed-up for an average of 7.9 years were included in the current analysis. Circadian 42 misalignment was defined as discrepancies between self-reported chronotype and 43 44 accelerometer-derived midpoint of sleep to detect its association with CMDs. Incident CMDs were derived from primary care, hospital inpatient, death registry, and self-reported source of 45 data. Cox proportional hazards regression models were used to compute the hazard ratio (HR) 46 47 and confidence intervals (CIs) on the association between circadian misalignment (quintiles of residuals of midsleep on chronotype) and incident CMDs. 48

**Results:** U-shaped associations were found of the circadian misalignment with incident T2D and CHD after adjusting the potential confounders. Compared to individuals with aligned midsleep and circadian preferences (Q3), those with advanced and delayed circadian misalignment had higher risks of T2D [HR (95%CI) 1.22 (1.03, 1.45) in Q1 and 1.39 (1.18, 1.62) in Q5]. However, only delayed circadian misalignment was significantly associated with an increased risk of CHD [HR (95%CI) 1.15 (1.01, 1.31) in Q4 and 1.16 (1.02, 1.33) in

55	Q5]. Liver function, lipid and glucose metabolism, and inflammatory markers partially
56	explained the observed circadian misalignment and CMDs association (mediation proportion
57	12.3-44.6% for T2D, 8.8-20.5% for CHD). Moreover, the association between delayed
58	circadian misalignment and CMDs was more prominent in women (for T2D, $P_{interaction}=0.03$ )
59	and in younger adults (for CHD, $P_{interaction}=0.02$ ) compared to their counterparts.
60	Additionally, early chronotype [HR (95%CI): 1.19 (1.06, 1.34)] rather than late chronotype
61	was associated with an increased risk of incident T2D.
62	Conclusion: Both advanced and delayed circadian misalignment were associated with
63	increased risks of CMDs, suggesting potential benefits of aligning actual sleep-wake cycles
64	with individual circadian preferences.
65	
66	Keywords: circadian misalignment, chronotype, diabetes, cardiometabolic diseases, UK
67	Biobank
68	

#### 70 Novelty and Significance

#### 71 What is known?

72	•	Cardiometabolic diseases such as type 2 diabetes, coronary heart disease, and
73		cerebrovascular diseases have become major concerns in global public health over
74		recent decades.
75	•	Evidence has linked several circadian disruption indicators to adverse health
76		outcomes: People living with late chronotype (circadian preference), late sleep
77		timing, long social jetlag (the difference between midsleep on work-free days and
78		work days), and shift work were prone to introduce circadian disruptions and had
79		higher risks of cardiometabolic diseases.
80	•	Little is known about whether and how the misalignment between circadian
81		preference and actual sleep-wake cycle is associated with cardiometabolic
82		diseases, particularly in large prospective cohort studies.
83	W	hat New Information Does This Article Contribute?

This is the first study to propose a new metrics (misalignment between circadian
 preference and actual sleep-wake cycle) to shed some lights on quantifying human
 circadian disruption in general population of differed work schedule and in
 population with less disrupted circadian rhythm.

• Both advanced and delayed sleep-wake cycle comparing to individual circadian

89 preference were associated with increased risks of cardiometabolic diseases.

- 90 Population may benefit from keeping an actual sleep-wake cycle in accordance
- 91 with their circadian preference.
- Early chronotype rather than late chronotype were found to associate with an
- 93 increased risk of incident T2D, independent of actual sleep-wake cycle.
- Age and sex modified the associations between circadian misalignment and
- 95 cardiometabolic diseases, while liver function, lipid and glucose metabolism, and
- 96 inflammatory markers partially mediated the associations.

# 97 Introduction

98	Cardiometabolic diseases (CMDs) such as type 2 diabetes (T2D), coronary heart
99	disease (CHD), and cerebrovascular diseases have become major concerns in global
100	public health over recent decades <sup>1</sup> . The multifactorial nature of the etiology of these
101	diseases involves a complex interplay of genetic, lifestyle, and environmental factors,
102	presenting great challenges on the prevention and prognosis of CMDs <sup>2</sup> . Therefore,
103	more efforts are needed to develop potential strategies to combat this escalating
104	phenomenon.
105	Circadian disruption indicated a wide range of misalignment upon individual
106	internal-internal timing as well as internal-external rhythm <sup>3</sup> . In field-based studies,
107	metrics for circadian disruption mainly rely on rest-activity measurement and
108	disrupted sleep behavior, e.g., social jetlag and shift work <sup>3</sup> . Epidemiological evidence
109	suggested that people living with late chronotype (circadian preference), late sleep
110	timing, long social jetlag (the difference between midsleep on work-free days and
111	work days), and shift work were prone to introduce circadian disruptions <sup>4</sup> and had
112	higher risks of CMDs <sup>5-9</sup> . However, current widely used proxies for circadian
113	disruption (such as social jetlag and shift work) either largely require regular work
114	schedule, or lack of generalizability to the general population who works non-shift
115	and less deviated from internal clock <sup>10</sup> . In addition, the majority of prior
116	epidemiological studies on circadian disruptions and CMDs were cross-sectional
117	designs <sup>6, 11, 12</sup> , only very limited prospective analysis was conducted in large
118	population <sup>13</sup> . Furthermore, advancements in sensor element technology and

119	accelerometer now allow the objective measurement of human sleep-wake cycle,
120	physical activity, and ambient environmental zeitgebers. Unlike biomarkers that
121	objectively measured human circadian rhythm requiring repeated or invasive
122	procedures <sup>14, 15</sup> , accelerometers enable a non-intrusive way to consistent tracking rest-
123	activity cycles <sup>14-16</sup> . Notably, over 80% population in a large database (the Munich
124	ChronotType Questionnaire database) reported using an alarm clock and accumulated
125	sleep debts during working week <sup>17</sup> , indicating a large proportion of population suffer
126	from misalignment between circadian preference and their actual sleep-wake cycle.
127	However, little is known about whether and how the misalignment between circadian
128	preference and actual sleep-wake cycle is associated with CMDs, particularly in large
129	prospective cohort studies.
130	Thus, based on a large-scale cohort study, the UK Biobank, we used the
131	information on accelerometer-derived sleep-wake cycle, the self-reported circadian
132	preference, and comprehensive diseases diagnosis resources 1) to prospectively
133	analyze the association of circadian misalignment with CMDs such as T2D, CHD,
134	and stroke, and 2) to reveal the potential mechanism underlying the relationship
135	between circadian misalignment and CMDs, through mediation analysis by plasma
136	biomarkers and anthropometric indices.
137	
138	Methods
139	Study design and participants

140 The UK Biobank, initiated in 2006-2010, is a large-scale prospective cohort study

141	containing comprehensive health information from over half a million adult UK
142	participants. The UK Biobank was granted ethical approval from the North West
143	Multi-center Research Ethical Committee (reference # 11/NW/0382) and research is
144	performed in accordance with the Declaration of Helsinki. This research has been
145	conducted using the UK Biobank Resource under application number 96083.
146	Among 502,505 participants at baseline in the UK Biobank, 74,123 participants
147	with complete and valid information on both baseline sleep questionnaire and
148	accelerometer derived information were included, after further excluding 7,052
149	participants with prevalent diabetes, stroke, or CHD at the time of monitoring activity,
150	389 participants with baseline random glucose level $\geq$ 11.1 mmol/L or HbA1c $\geq$ 48
151	mmol/mol, 5,418 participants reported jobs involves shift work, and 299 participants
152	with measured sleep duration $< 4$ hours or $> 12$ hours, 60,965 participants were
153	included in final analysis (Figure 1).
154	
155	Sleep assessment
156	Sleep status was evaluated through both subjective touchscreen sleep questionnaires
157	and objective actigraphy monitors.
158	Sleep questionnaire
159	At baseline recruitment, information on personal chronotype, 24h sleep duration,
160	snoring, insomnia, and daytime sleepiness was collected by a self-administrated
161	touchscreen sleep questionnaire. They were collected by the following questions: "Do
162	you consider yourself to be? (definitely a 'morning' person, more a 'morning' person

163	than an 'evening' person, more an 'evening' person than a 'morning' person,
164	definitely an 'evening' person, do not know, prefer not to answer)", "About how many
165	hours sleep do you get in every 24 hours? (please include naps)", "Does your partner
166	or a close relative or friend complain about your snoring? (yes, no, do not know,
167	prefer not to answer)", "Do you have trouble falling asleep at night or do you wake up
168	in the middle of the night? (never/rarely, sometimes, usually, prefer not to answer)","
169	How likely are you to doze off or fall asleep during the daytime when you don't mean
170	to? (e.g., when working, reading or driving) (never/rarely, sometimes, often, do not
171	know, prefer not to answer, all of the time)". For all the above questions, answers with
172	"do not know", "prefer not to answer" were considered as missing. Healthy sleep
173	quality score was calculated from questionnaire derived chronotype, insomnia, snore,
174	daytime sleepiness, and sleep duration, see Supplementary TableS1.
175	
176	Actigraphy
177	During June 2013 and January 2016, physical activity and sleep measurements were
178	recorded via a wrist-worn accelerometer (Axivity AX3), which is a commercial
179	version of the Open Movement AX3 open-source sensor
180	(https://github.com/digitalinteraction/openmovement) designed by Open Lab,
181	Newcastle University. Exquisite processes on data collection and curation have been

- 182 described previously<sup>18</sup>. Briefly, participants were instructed to wear the accelerometer
- 183 upon receipt and proceed with their usual routines, affixing it to their dominant wrist.
- 184 They were notified that the device would activate automatically upon delivery and

185	deactivate after a week. At the end of this period, participants returned the device to
186	the central office using a provided pre-paid envelope. R package GGIR was used to
187	clearing, calibrating, and deriving information on timing of sleep, moderate to
188	vigorous physical activity, and light exposure <sup>19, 20</sup> .
189	
190	Ascertainment of circadian misalignment
191	The morning-evening preference, chronotype, was collected by one validated question
192	from the Horne and Östberg Morningness-Eveningness Questionnaire (MEQ) <sup>21</sup> . This
193	question indicated a good correlation with the overall score of the MEQ $(r = 0.72)^{22}$ ,
194	and was also employed in other large cohort studies to indicate individual circadian

195 preference<sup>13, 23</sup>. Additionally, information on participants timing of onset and end of

196 sleep was collected by wearing an actigraphy on dominant wrist through seven

197 consecutive days and derived by R package GGIR. Nighttime sleep duration was

198 calculated as the difference between time point of sleep end and sleep onset. Midsleep

199 of weekdays, weekend, and weekly average can be calculated using the following

200 formula, using the average value of sleep onset and sleep duration on weekdays,

201 weekend, and the whole week, respectively.

$$Midsleep = sleeponset + \frac{1}{2}sleep duration$$

The misalignment between circadian preference (chronotype) and midsleep was calculated as the residuals of midsleep on chronotype or the difference between midsleep and chronotype (subtracting group numbers of chronotype from midsleep)<sup>24</sup>, detailed calculation and categorization can be found in **Supplementary Method**.

206

#### 207 Cardiometabolic outcomes

- 208 Newly onset of T2D, CHD, and stroke (including ischemic stroke and hemorrhage
- stroke subtypes) were individually evaluated and collectively considered when
- 210 calculating CMD incidence. Data on data showcase-first occurrence (Category 1712)
- 211 were used to derive the first occurrence date of diseases. Two main classification
- systems of clinical coding were used in the linked health data: International
- 213 Classification of Diseases (ICD) and Read. Information on primary cares (Read v2
- and Read CTV3), hospital inpatient (ICD10 and ICD9), death register (ICD10),
- 215 cancer register (ICD10 and ICD9), and self-reported medical condition were gathered
- and mapped to 3-character ICD-10 to ascertain the source and date of the first
- 217 occurrence of diseases. Detailed method can be found here
- 218 (https://biobank.ndph.ox.ac.uk/showcase/ukb/docs/first\_occurrences\_outcomes.pdf).
- 219 ICD code and field ID of outcomes were described in **Supplementary table S2**.
- 220 Incident cases were defined as cases with a later date of first occurrence in
- 221 comparison with the date of measurement of baseline information and accelerometer.

222

# 223 Covariates

- 224 Baseline information on demographic and socioeconomic status (age, sex, education,
- 225 Townsend deprivation index, region, ethnic group, employment status) and family
- history of diseases were collected in assessment center when participants were
- 227 initially recruited. Lifestyle factors including drinking and smoking status, tea and

228	coffee intake, as well as a detailed 29-item food frequency questionnaire on dietary
229	intakes were also evaluated in assessment center by touchscreen questionnaire. Diet
230	intake information was converted to a Mediterranean diet score to indicate dietary
231	quality <sup>25</sup> .
232	Additionally, baseline body weight, height, waist circumference, hip circumference,
233	and blood pressure were measured in assessment center under standard process. Body
234	mass index was calculated as weight (kg) divided by height (m) squares, and waist-
235	hip-ratio was also calculated. Blood samples were collected at recruitment, separated
236	by components and stored at UK Biobank (-80°C and LN2). Sample collection and
237	processing has been previously described in detail
238	(https://biobank.ndph.ox.ac.uk/showcase/ukb/docs/biomarker_issues.pdf). A range of
239	key biochemistry markers (hepatic and renal function, inflammatory cytokines, lipids
240	and glucose metabolism) were used in the current analysis. Levels of glucose and
241	HbA1c at baseline were employed to identify participants with prevalent diabetes.
242	Levels of Low-Density Lipoprotein was also used in analysis, as it was closely related
243	to cardiometabolic outcomes <sup>26</sup> .
244	

# 245 Statistical analysis

All statistical analyses were performed using SAS 9.4 (SAS Institute Inc) and R

247 version 3.4.2. Two-sided P < 0.05 were regarded as the level of significance.

248 Descriptive data of participants at baseline were shown as number (%) for categorical

249 variables and mean (standard deviation) for continuous variables. See

250	Supplementary Method for the adjusted circadian misalignment according to
251	baseline characteristics and selection of covariates in the following models.
252	Cox proportional hazard models were used to investigate the associations
253	between circadian misalignment (quintiles of residuals of midsleep on chronotype)
254	and incident cardiometabolic events. All cox models have passed the proportional
255	hazards assumption by Schoenfield Residuals Test. Model 1 was adjusted for age
256	(tertiles), sex (men/women), and ethnic group (White British/Non-White British), and
257	Model 2 was additionally adjusted for region (urban/town/village), Townsend
258	deprivation index (tertiles), employment (in-paid employment/retired/without fixed
259	employment), qualification (college or university degree/A levels or equivalent/O
260	levels or GCSEs or equivalent/none of the above), and ambient noise level (tertiles).
261	Model 3 (main model) was further adjusted for smoking status (never/ever/current),
262	drinking status (never/ever/current), tea consumption (<2/2-4/≥5 cups), coffee
263	consumption (0/0-2/ $\geq$ 3 cups), accelerometer-derived moderate to vigorous physic
264	activity (tertiles), and healthy sleep quality score (<2/2-3/>3). All continuous
265	covariates were converted to tertiles to clearer show their relationship with circadian
266	misalignment (Figure S1) and CMDs. Since missing values for all covariates were
267	less than 6% (5.9% for healthy sleep quality score, and 1.2% for ambient noise level,
268	and less than 0.2% for other covariates), they were imputed as the mode <sup>12</sup> . Plots on
269	restricted cubic splines (four knots on $0.05$ , $0.35$ , $0.65$ , and $0.95$ , respectively) and P
270	for nonlinear (ANOVA test <sup>27</sup> ) were used to show the nonlinear relationship between
271	circadian misalignment and cardiometabolic events. Moreover, risk of

272	cardiometabolic events were also evaluated by circadian misalignment using
273	difference between midsleep and chronotype (advanced/intermediate/delayed group),
274	as well as chronotype and midsleep individually. When investigating the association
275	of midsleep and chronotype with CMDs, they were further mutually adjusted.
276	Sensitivity analyses were conducted by 1) recategorizing the main exposure,
277	circadian misalignment (residuals of midsleep on chronotype), into three groups
278	[advanced (Q1), intermediate (Q2+Q3+Q4), delayed (Q5) group]; 2) recalculating the
279	main exposure, circadian misalignment, as the absolute value of the residuals of
280	midsleep on chronotype, and categorized it into tertiles. The linear trend of HRs over
281	tertiles was assessed by $\chi^2$ test using these tertile numbers as continuous variables; 3)
282	based on main model (Model 3), additionally adjusted for family history of diabetes
283	(when outcome is T2D), family history of cardiovascular diseases (when outcome is
284	stroke and CHD), or family history of diabetes and cardiovascular diseases (when
285	outcome is CMDs), and time span between baseline recruitment and accelerometer
286	assessment, as they were suggested confounders in previous studies. Age was adjusted
287	in the form of continuous variable to reduce potential residual confounding; 4) Based
288	on main model, further adjusted for BMI, LDL, and SBP, as they may act both as
289	underlying mediators and confounders; 5) excluding upper and lower 0.5% value of
290	residuals of midsleep on circadian preference; 6) calculating propensity score to
291	balance the distribution of baseline characteristics among differed circadian
292	misalignment group. Propensity score weights for multiple treatments and average
293	treatment effect on the treated was calculated by the R package Twang and using the

294	method of gradient boosting machine <sup>29, 30</sup> ; 7) using ICD-10 code E11 instead of
295	pooling E11 and E14 together to define T2D; and 8) including participants who
296	worked with shift work in analysis, as shift work was an important contributor of
297	circadian misalignment.
298	In secondary analysis, causal mediation analyses were conducted by R package
299	CMAverse <sup>28</sup> . Average total effect hazard ratio, nature direct hazard ratio, nature
300	indirect hazard ratio, and proportion mediated by potential mediators were shown.
301	Mediators were log-transformed and standardized to show HRs (95% CI) per standard
302	deviation. Proportional hazards assumptions were also confirmed. See
303	Supplementary Method for the selection of potential mediators. Furthermore,
304	subgroup analyses were conducted by age (<57 /≥57 years (median)), sex
305	(women/men), ethnic (White British/non-White British), residence (Urban/town or
306	village), socioeconomic status ( <median 2median),="" and="" healthy="" quality="" score<="" sleep="" td=""></median>
307	( $<4/\geq4$ ). The multiplicative interaction between characteristics and circadian
308	misalignment was also detect by additionally adding an interaction term to the model.
309	
310	Results
311	Baseline characteristics and risk factors of delayed circadian misalignment
312	60,965 participants aged 39 to 70 years at baseline were included in analysis.
313	Compared to advanced circadian misalignment group, participants of delayed
314	circadian misalignment group were prone to be older, women, and non-White British.
315	They were more likely to live in urban areas and be exposed to higher ambient noise

316	level, have lower education levels and socioeconomic status, and work without pay.
317	In terms of lifestyle, participants predisposed to delayed circadian misalignment
318	tended to be current smokers and drinkers, engage in less moderate to vigorous
319	physical activity, drink more tea and less coffee, and have worse sleep quality (Table
320	1 and Figure S1).
321	
322	Association between circadian misalignment and incident cardiometabolic events
323	During an average follow-up of 7.86 years, 1,526 (2.50%), 684 (1.12%), and 2,186
324	(3.59%) participants developed incident T2D, stroke, and CHD, respectively, yielding
325	an overall 4,084 (6.70%) participants developing CMDs in total.
326	After fully adjustment in main model (Model 3), compared to individuals with
327	matched midsleep and circadian preferences (Q3), both the advanced and delayed
328	circadian misalignment were associated with higher type 2 diabetes [HR (95%CI)
329	1.22 (1.03, 1.45) in Q1 and 1.39 (1.18, 1.62) in Q5] and CMDs [HR (95%CI) 1.12
330	(1.02, 1.25) in Q1 and 1.21 (1.10, 1.33) in Q5]. However, only delayed circadian
331	misalignment (Q4 and Q5) was significantly related to increased risk of CHD [HR
332	(95%CI) 1.15 (1.01, 1.31) in Q4 and 1.16 (1.02, 1.33) in Q5] (Table 2). Circadian
333	misalignment was not associated with incidence of stroke or stroke subtypes (Table 2
334	and Table S3). When calculating circadian misalignment by the difference between
335	midsleep and chronotype, participants with delayed circadian misalignment had
336	higher risk of developing T2D [HR (95%CI): 1.19 (1.06, 1.33)] and CMD [HR
337	(95%CI): 1.10 (1.03, 1.17)]. Consistently, neither type of circadian misalignment was

associated with incidence of stroke (Figure 2).

339	The "U-shaped" nonlinear associations of circadian misalignment with T2D
340	( $P_{nonlinear} < 0.001$ ), CHD ( $P_{nonlinear} = 0.03$ ), and CMD ( $P_{nonlinear} < 0.001$ ) were significantly
341	revealed through RCS plots (Figure S2). To detect the robustness of the relationship
342	between circadian misalignment and cardiometabolic outcomes, sensitivity analyses
343	were conducted and yielded consistent results (Table S4, Table S5, Figure S3).
344	In stratified analysis, consistent results among different ethnicity, residence,
345	socioeconomic status, and sleep quality subgroups were displayed. Notably, the
346	association between delayed circadian misalignment and CMDs was more prominent
347	in women (for T2D, $P_{interaction}=0.03$ ) or in population aged younger than 57 years, the
348	average age (for CHD, $P_{interaction}=0.02$ ) compared to their counterparts (Figure S4).
349	
350	Mediation analysis on the relationship between circadian misalignment and
350 351	Mediation analysis on the relationship between circadian misalignment and incident cardiometabolic events
350 351 352	Mediation analysis on the relationship between circadian misalignment and incident cardiometabolic events Mediation analysis indicated that liver function, blood lipid and glucose metabolism,
350 351 352 353	Mediation analysis on the relationship between circadian misalignment and incident cardiometabolic events Mediation analysis indicated that liver function, blood lipid and glucose metabolism, inflammatory factors, and anthropometric indices were associated with both circadian
350 351 352 353 354	Mediation analysis on the relationship between circadian misalignment and incident cardiometabolic events Mediation analysis indicated that liver function, blood lipid and glucose metabolism, inflammatory factors, and anthropometric indices were associated with both circadian misalignment and CMDs, independent of demographic, socioeconomics, and lifestyle
350 351 352 353 354 355	Mediation analysis on the relationship between circadian misalignment and incident cardiometabolic events Mediation analysis indicated that liver function, blood lipid and glucose metabolism, inflammatory factors, and anthropometric indices were associated with both circadian misalignment and CMDs, independent of demographic, socioeconomics, and lifestyle factors (Table S6-S8). Among them, anthropometric indices including BMI, WHR,
350 351 352 353 354 355 356	Mediation analysis on the relationship between circadian misalignment and incident cardiometabolic events Mediation analysis indicated that liver function, blood lipid and glucose metabolism, inflammatory factors, and anthropometric indices were associated with both circadian misalignment and CMDs, independent of demographic, socioeconomics, and lifestyle factors (Table S6-S8). Among them, anthropometric indices including BMI, WHR, and blood pressure introduced the largest proportion of mediation effect (44.6%)
350 351 352 353 354 355 356 357	Mediation analysis on the relationship between circadian misalignment andincident cardiometabolic eventsMediation analysis indicated that liver function, blood lipid and glucose metabolism,inflammatory factors, and anthropometric indices were associated with both circadianmisalignment and CMDs, independent of demographic, socioeconomics, and lifestylefactors (Table S6-S8). Among them, anthropometric indices including BMI, WHR,and blood pressure introduced the largest proportion of mediation effect (44.6%)between circadian misalignment and T2D, whereas liver function, blood lipids and
350 351 352 353 354 355 356 357 358	Mediation analysis on the relationship between circadian misalignment andincident cardiometabolic eventsMediation analysis indicated that liver function, blood lipid and glucose metabolism,inflammatory factors, and anthropometric indices were associated with both circadianmisalignment and CMDs, independent of demographic, socioeconomics, and lifestylefactors (Table S6-S8). Among them, anthropometric indices including BMI, WHR,and blood pressure introduced the largest proportion of mediation effect (44.6%)between circadian misalignment and T2D, whereas liver function, blood lipids andglucose metabolism, and inflammatory factors mediated 12.3%, 24.5%, 20.0%
350 351 352 353 354 355 356 357 358 359	Mediation analysis on the relationship between circadian misalignment andincident cardiometabolic eventsMediation analysis indicated that liver function, blood lipid and glucose metabolism,inflammatory factors, and anthropometric indices were associated with both circadianmisalignment and CMDs, independent of demographic, socioeconomics, and lifestylefactors (Table S6-S8). Among them, anthropometric indices including BMI, WHR,and blood pressure introduced the largest proportion of mediation effect (44.6%)between circadian misalignment and T2D, whereas liver function, blood lipids andglucose metabolism, and inflammatory factors mediated 12.3%, 24.5%, 20.0%

360	CHD	, liver	function.	, blood li	pids and	glucose	metabolism,	inflammator	y factors.	, and
-----	-----	---------	-----------	------------	----------	---------	-------------	-------------	------------	-------

- anthropometric indices introduced 8.8%, 9.1%, 13.7%, and 20.5% of mediation
- 362 effects between circadian misalignment and CHD, respectively (Table 3).
- 363

#### 364 Association between other circadian rhythm proxies and incident

# 365 cardiometabolic events

- 366 After multiple adjustments, early chronotype [HR (95%CI): 1.19 (1.06, 1.34)] and late
- midsleep [1.21 (1.07, 1.36)] were both associated with increased risk of incident T2D.
- 368 Meanwhile, neither chronotype nor midsleep was associated with CHD or stroke
- 369 (Figure 2). Notably, the significant association [HR (95%CI) 1.22 (1.03, 1.44)]
- 370 between late chronotype and T2D disappeared after further adjusting for midsleep
- 371 [1.08 (0.91, 1.28)].

#### 372 Discussion

373	In this large-scale population-based cohort study, we proposed a new metrics for
374	circadian misalignment by calculating the discrepancy between circadian preference
375	and accelerometer-derived actual sleep-wake cycle, and prospectively revealed a U-
376	shaped association of circadian misalignment with T2D and CHD. Our results
377	indicated that both advanced and delayed sleep-wake cycle in relation to individual
378	circadian preference were associated with increased risks of CMDs, although the
379	association was stronger in the delayed than the advanced group.
380	Our findings on the relationship between circadian misalignment and CMDs
381	were consistent with previous cross-sectional studies regarding circadian disruption
382	(social jetlag <sup>6</sup> , shift work <sup>11</sup> , or alignment between light cycle and sleep cycle <sup>12</sup> ),
383	although circadian misalignment in this study was measured by different metrics.
384	Additionally, the Nurses' Health Study also revealed similar prospective association
385	between circadian misalignment (chronotype and shift work) and T2D <sup>13, 23</sup> . Unlike
386	most studies that focusing on chronotype <sup>9</sup> and shift work <sup>7</sup> individually, the Nurses'
387	Health Study <sup>13</sup> was the first large cohort study to detect circadian misalignment by
388	examining the interaction between chronotype and shift work, revealing that an
389	increased risk of T2D was predominantly emerged in nurses with long night shifts and
390	an early chronotype, and was also seen in participants with long daytime work but a
391	late chronotype. However, it remains unclear whether the mismatch between
392	chronotype and actual sleep-wake cycle was associated with adverse health outcomes,
393	especially in population working non-shift and less-deviated from their internal clock.

Our findings by considering both circadian preference and actual sleep-wake cycle,

395 were in line with, and further expanded these discoveries in a more quantified manner

396 regarding circadian disruption and in both men and women population.

To date, shift work and social jetlag were the most commonly used proxies for 397 circadian disruption in large scale population-based studies<sup>3</sup>. Other less-employed 398 metrics such as composite phase deviation<sup>10</sup> and delayed onset of melatonin either 399 lack employment in large population or imposed considerable burdens on study 400 subjetcs<sup>14, 15</sup>. Participants working night shift<sup>11, 31</sup> is a commonly used metrics for 401 circadian disruption, not only for its easily-collected nature but also for having the 402 highest levels of deviation relative to internal clock<sup>3</sup>. Night shifts represent the most 403 strenuous shift for most individuals, however, the association of circadian disruption 404 405 on diseases for vast non-shift workers with less disturbed disruption also merits to be explored. On the other hand, since put forward in 2006, social jetlag has been widely 406 used as a good proxy for circadian disruption, and has been associated with various 407 adverse health outcomes<sup>32</sup>. It was defined by the discrepancy between social clock 408 and biological clock while employ midpoint of sleep on work days and work-free 409 days to respectively indicate the above two clocks. However, sleep compensation<sup>33</sup> 410 made it hard to accurately indicate biological clock by midsleep on work-free days. 411 Moreover, it is not suitable for population of retired or without fixed work. The 412 metrics of circadian misalignment in our analyses was defined by the discordance 413 between self-reported circadian preference and actual sleep-wake cycle, it could be 414 analyzed as a continuous variable to detect the U-shaped relationship between 415

416	circadian misalignment and CMDs. It is also able to characterize circadian disruption
417	on population of non-shiftwork, retired, and without fixed work.
418	We additionally revealed that early chronotype, rather than late chronotype, was
419	associated with increased risk of T2D, which was inconsistent with previous
420	evidence <sup>23, 34</sup> . Cross-sectional studies <sup>35, 36</sup> and limited prospective cohort study <sup>23</sup>
421	revealed that late or evening chronotype were associated with higher risk of disrupted
422	glucose homeostasis and T2D. However, to our knowledge, most existing studies <sup>35, 36</sup>
423	did not explore if the relationship between chronotype and health outcomes was
424	independent of actual sleep-wake cycle. Our analysis indicated that after adjusting for
425	sleep-wake cycle, the risk association of late chronotype decreased to null.
426	Meanwhile, one large prospective analysis also revealed that participants reporting a
427	"definite evening" chronotype were more likely to exhibit unhealthy lifestyle, which
428	might largely explain the association with increased diabetes risk <sup>23</sup> . Thus, the
429	association between late chronotype and T2D may at least partially explained by late
430	sleep-wake cycle. Notably, a previous analysis conducted in UKB population also
431	suggested that "definite morning" was associated with higher risk of CMDs, when
432	classifying participants into four groups (definite morning, morning, evening, definite
433	evening) <sup>37</sup> . However, most studies <sup>8, 13</sup> generally categorized the chronotype into two
434	or three groups, making it challengeable to reveal the nonlinear relationship between
435	chronotype and health outcomes, which are needed to be confirmed in future studies.
436	The potential mechanism between circadian misalignment and CMDs remains
437	unclear. A recent compendium highlighted several diurnal and circadian mechanisms

438	underlying cardiovascular and cerebrovascular diseases <sup>38</sup> : Circadian misalignment
439	may affect immune function to promote systemic inflammation and exacerbate
440	cardiovascular damage <sup>39</sup> . There is also evidence that circadian misalignment increases
441	the risk of cardiovascular events by causing hypoxia and myocardial ischemia-
442	reperfusion injury <sup>40</sup> . Besides, molecular and physiological processes that regulate
443	cardiovascular metabolism could also be associated with circadian misalignment
444	through the interaction of circadian genes (CLOCK, BMAL1, period, timeless, CRY,
445	etc.) and signaling pathways such as classic signal-response coupling (termed
446	reactionary mechanisms) or temporally orchestrate metabolic pathways in
447	preparation for predicted stimuli/stresses (termed anticipatory mechanisms) <sup>41</sup> . We
448	found that the association between circadian misalignment and CMDs may at least
449	partially mediated by liver function, lipid metabolism, inflammatory factors, and most
450	prominently, BMI and WHR, which may shed some light on the potential mechanism
451	linking circadian misalignment with cardiometabolic health outcomes. Moreover,
452	effect modification of sex on the relationship of circadian misalignment with CHD
453	and T2D was also revealed, which may be due to the sexual dimorphism of the
454	metabolism that contributed to sex differences in CMDs <sup>42</sup> . Meanwhile, age-related
455	variations in gut microbiota and metabolic profiling <sup>43</sup> may partially explain the
456	modulatory role of age on the circadian misalignment-CMD associations.
457	Additionally, we also found that women and older participants were more likely to
458	have delayed circadian misalignment in our study, which was associated with
459	increased risk of CMDs.

460	To our knowledge, this is the first study to examine the association between
461	misalignment of circadian preference and actual sleep-wake cycle and
462	cardiometabolic events. Moreover, validated accelerometers were employed to
463	objectively measure participants' sleep-wake cycles, whereas previous measurements
464	of sleep-wake cycles, especially in prospective studies, were mostly based on the
465	questionnaires <sup>44</sup> .
466	Despite the above strengths, several limitations were also worth noting. In
467	addition to the relatively older age as well as higher socioeconomic status of UKB
468	participants, measurement bias may generate from accelerometer derived sleep-
469	timing, as accelerometer detected inactivity time rather than sedentary time <sup>45</sup> .
470	However, good agreements (89-97%) between accelerometer-derived sleep status and
471	polysomnography have been verified <sup>46</sup> , and comparing to waist-worn, the wrist-worn
472	placement could improve capability of assessing sleep behaviors <sup>47</sup> . Moreover, self-
473	reported circadian preference based on a single question from MEQ was employed.
474	As a most widely used and easily collected circadian indicator, validity of MEQ score
475	in relation to objectively measured circadian markers <sup>48</sup> , as well as that of this question
476	to overall score <sup>22</sup> has been fully investigated. Another limitation is that there is an
477	average 5.8 years of difference between the measurement of circadian preference and
478	real sleep-wake cycle. However, evidence has revealed circadian preference is a

479 relatively stable characteristic for human being $^5$ . Besides, we included the time gap

480 between them as a potential confounder in sensitivity analysis and also tested the

481 interaction between the time gap and major exposures, which resulted no effect

482	modification. A previous study in UK Biobank also indicated most of basic
483	characteristics did not change overtime <sup>49</sup> . Moreover, because only one measurement
484	on actual sleep-wake cycle was conducted, eternal time bias may happen when
485	participants change their usual sleep-wake time. In addition, using a simple time point
486	on midsleep to indicate sleep-wake cycle may lose detailed information on the phase
487	and amplitude of this cycle. Nevertheless, it is an easy way to refer to sleep-wake
488	cycle and subsequently to calculate circadian misalignment, and is appropriate for
489	conducting circadian measurement on large-scale population studies <sup>17</sup> . Lastly, due to
490	the observational nature and the possibility of residual confounding, our study could
491	not establish causality.
492	In conclusion, both advanced or delayed circadian misalignment were associated
493	with increased risk of cardiometabolic events. Population may benefit from keeping
494	an actual sleep-wake cycle in accordance with their circadian preference. This study
495	proposed a new metrics regarding circadian disruption, and may shed some light on
496	the prevention and management of population with high risk of developing
497	cardiometabolic events. Our results are needed to be confirmed by further studies that
498	objectively measure personal circadian preference.
499	
500	Author contribution:

501 YC, XG, and LS conceived and designed this study. YC, XX, ZZ, and HD researched

502 data. YC, XX and LH analyzed the data. YC, TG, HY, XG and LS interpreted the

503 results and drafted the manuscript. XG and LS supervised the study. All authors

		1	•	1	• •	0.1	•			1	. 1	1
504	contributed	to the	review	and	revision	of the	manuscrin	t and	l agree 1	n he	accountab	1e
50-	continuuteu	to the		anu		or the	manuserip	ιanc	i agree i	000		лu

505 for all aspects of work ensuring integrity and accuracy.

506

507	Ackno	wled	lgement:
-----	-------	------	----------

- 508 The most important acknowledgement is to the participants in UK Biobank and the
- 509 members of the UK Biobank teams, as well as to all members of team of the current
- analysis for their valuable help. The authors also appreciate the helpful comments on
- 511 this manuscript provided by the reviewers and editors.

512

# 513 Sources of funding:

- 514 This study was funded by the Major Project of the Ministry of Science and
- 515 Technology of China (2023YFC2506704) and the Startup grant from Fudan
- 516 University (JIF201068Y and IDF201026Y).

517

#### 518 **Disclosures:**

519 The authors declare no conflict of interest.

520

# 521 Data availability:

- 522 This research has been conducted using the UK Biobank Resource under Application
- 523 Number 96083. Data from UK Biobank is accessible to eligible researchers via

524 applying to www.ukbiobank.ac.uk.

# 526 Ethic approvement:

- 527 The UK Biobank was granted ethical approval from the North West Multi-center
- 528 Research Ethical Committee (reference # 11/NW/0382) and research is performed in
- 529 accordance with the Declaration of Helsinki.

531 1. Stefan N and Schulze MB. Metabolic health and cardiometabolic risk clusters:
532 implications for prediction, prevention, and treatment. *Lancet Diabetes Endocrinol.*

533 2023;11:426-440.

- 2. Poveda A, Chen Y, Brändström A, Engberg E, Hallmans G, Johansson I, Renström F,
- 535 Kurbasic A and Franks PW. The heritable basis of gene-environment interactions in 536 cardiometabolic traits. *Diabetologia*. 2017;60:442-452.
- 537 3. Vetter C. Circadian disruption: What do we actually mean? The European journal of
- 538 *neuroscience*. 2020;51:531-550.
- 539 4. Fishbein AB, Knutson KL and Zee PC. Circadian disruption and human health. *The*
- 540 *Journal of clinical investigation*. 2021;131.
- 541 5. Roenneberg T, Pilz LK, Zerbini G and Winnebeck EC. Chronotype and Social Jetlag: A
- 542 (Self-) Critical Review. *Biology*. 2019;8.
- 543 6. Cespedes Feliciano EM, Rifas-Shiman SL, Quante M, Redline S, Oken E and Taveras
- 544 EM. Chronotype, Social Jet Lag, and Cardiometabolic Risk Factors in Early Adolescence.
- 545 *JAMA pediatrics*. 2019;173:1049-1057.
- 546 7. Kecklund G and Axelsson J. Health consequences of shift work and insufficient sleep.
- 547 *BMJ (Clinical research ed)*. 2016;355:i5210.
- 548 8. Lin K, Song M and Giovannucci E. Evening Chronotype, Circadian Misalignment, and
- 549 Metabolic Health: Implications for Diabetes Prevention and Beyond. Annals of internal
- 550 *medicine*. 2023;176:1422-1423.
- 551 9. Reutrakul S, Hood MM, Crowley SJ, Morgan MK, Teodori M, Knutson KL and Van

552 Cauter E. Chronotype is independently associated with glycemic control in type 2 diabetes.

553 Diabetes care. 2013;36:2523-9.

554 10. Fischer D, Vetter C and Roenneberg T. A novel method to visualise and quantify

555 circadian misalignment. *Scientific reports*. 2016;6:38601.

- 556 11. Sooriyaarachchi P, Jayawardena R, Pavey T and King NA. Shift work and the risk for
- 557 metabolic syndrome among healthcare workers: A systematic review and meta-analysis.
- 558 Obesity reviews : an official journal of the International Association for the Study of Obesity.
- 559 2022;23:e13489.
- 560 12. Xiao Q, Durbin J, Bauer C, Yeung CHC and Figueiro MG. Alignment Between 24-h Light-
- 561 Dark and Activity-Rest Rhythms Is Associated With Diabetes and Glucose Metabolism in a

562 Nationally Representative Sample of American Adults. *Diabetes care*. 2023;46:2171-2179.

- 563 13. Vetter C, Devore EE, Ramin CA, Speizer FE, Willett WC and Schernhammer ES.
- 564 Mismatch of Sleep and Work Timing and Risk of Type 2 Diabetes. *Diabetes care*. 565 2015;38:1707-13.
- 566 14. Braun R, Kath WL, Iwanaszko M, Kula-Eversole E, Abbott SM, Reid KJ, Zee PC and

567 Allada R. Universal method for robust detection of circadian state from gene expression.

- 568 Proceedings of the National Academy of Sciences of the United States of America.
- 569 2018;115:E9247-e9256.
- 570 15. Wittenbrink N, Ananthasubramaniam B, Munch M, Koller B, Maier B, Weschke C, Bes F,
- 571 de Zeeuw J, Nowozin C, Wahnschaffe A, Wisniewski S, Zaleska M, Bartok O, Ashwal-Fluss R,
- 572 Lammert H, Herzel H, Hummel M, Kadener S, Kunz D and Kramer A. High-accuracy
- 573 determination of internal circadian time from a single blood sample. The Journal of clinical

574 *investigation*. 2018;128:3826-3839.

- 575 16. Meyer N, Harvey AG, Lockley SW and Dijk DJ. Circadian rhythms and disorders of the
- 576 timing of sleep. *Lancet (London, England)*. 2022;400:1061-1078.
- 577 17. Roenneberg T. How can social jetlag affect health? *Nature reviews Endocrinology*.
- 578 2023;19:383-384.
- 579 18. Doherty A, Jackson D, Hammerla N, Plötz T, Olivier P, Granat MH, White T, van Hees
- 580 VT, Trenell MI, Owen CG, Preece SJ, Gillions R, Sheard S, Peakman T, Brage S and
- 581 Wareham NJ. Large Scale Population Assessment of Physical Activity Using Wrist Worn
- 582 Accelerometers: The UK Biobank Study. *PloS one*. 2017;12:e0169649.
- 583 19. Migueles J, Rowlands A, Huber F, Sabia S and van Hees V. GGIR: A Research
- 584 Community-Driven Open Source R Package for Generating Physical Activity and Sleep
- 585 Outcomes From Multi-Day Raw Accelerometer Data. Journal for the Measurement of Physical
- 586 *Behaviour*. 2019;2:188-196.
- 587 20. van Hees VT, Sabia S, Anderson KN, Denton SJ, Oliver J, Catt M, Abell JG, Kivimäki M,
- 588 Trenell MI and Singh-Manoux A. A Novel, Open Access Method to Assess Sleep Duration
- 589 Using a Wrist-Worn Accelerometer. *PloS one*. 2015;10:e0142533.
- 590 21. Horne JA and Ostberg O. A self-assessment questionnaire to determine morningness-
- 591 eveningness in human circadian rhythms. International journal of chronobiology. 1976;4:97-
- 592 110.
- 593 22. Megdal SP and Schernhammer ES. Correlates for poor sleepers in a Los Angeles high
  594 school. *Sleep medicine*. 2007;9:60-3.
- 595 23. Kianersi S, Liu Y, Guasch-Ferré M, Redline S, Schernhammer E, Sun Q and Huang T.

- 596 Chronotype, Unhealthy Lifestyle, and Diabetes Risk in Middle-Aged U.S. Women : A
- 597 Prospective Cohort Study. Annals of internal medicine. 2023;176:1330-1339.
- 598 24. Chatterjee S, Cook RD and Weisberg S. Residuals and Influence in Regression. 1982.
- 599 25. Trichopoulou A, Costacou T, Bamia C and Trichopoulos D. Adherence to a
- 600 Mediterranean diet and survival in a Greek population. *The New England journal of medicine*.
- 601 2003;348:2599-608.
- 602 26. Holmes MV, Ala-Korpela M and Smith GD. Mendelian randomization in cardiometabolic
- disease: challenges in evaluating causality. *Nature reviews Cardiology*. 2017;14:577-590.
- 604 27. Jianhua ZH, Charles K, Charles JS and Young KT. Functional ANOVA modeling for
- 605 proportional hazards regression. *The Annals of Statistics*. 2000;28:961-999.
- 606 28. Shi B, Choirat C, Coull BA, VanderWeele TJ and Valeri L. CMAverse: A Suite of
- 607 Functions for Reproducible Causal Mediation Analyses. Epidemiology (Cambridge, Mass).

608 2021;32:e20-e22.

- 29. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R and Burgette LF. A
- 610 tutorial on propensity score estimation for multiple treatments using generalized boosted
- 611 models. *Statistics in medicine*. 2013;32:3388-414.
- 30. Griffin BA, Sanchez R, Cefalu M, Ayer L, Coffman DL, Vegetabile BG, Pane JD, Burgette
- 613 LF and McCaffrey DF. Toolkit for Weighting and Analysis of Nonequivalent Groups. *Santa*614 *Monica, Calif: RAND Corporation, TL-A570-2.* 2020.
- 31. Drake CL, Roehrs T, Richardson G, Walsh JK and Roth T. Shift work sleep disorder:
  prevalence and consequences beyond that of symptomatic day workers. *Sleep.*2004;27:1453-62.

- 618 32. Wittmann M, Dinich J, Merrow M and Roenneberg T. Social jetlag: misalignment of
- 619 biological and social time. *Chronobiology international*. 2006;23:497-509.
- 620 33. Arora T, Chen MZ, Cooper AR, Andrews RC and Taheri S. The Impact of Sleep Debt on
- 621 Excess Adiposity and Insulin Sensitivity in Patients with Early Type 2 Diabetes Mellitus.
- 622 Journal of clinical sleep medicine : JCSM : official publication of the American Academy of
- 623 *Sleep Medicine*. 2016;12:673-80.
- 624 34. Fan M, Sun D, Zhou T, Heianza Y, Lv J, Li L and Qi L. Sleep patterns, genetic
- 625 susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK
- biobank participants. *Eur Heart J.* 2020;41:1182-1189.
- 627 35. Lotti S, Pagliai G, Colombini B, Sofi F and Dinu M. Chronotype Differences in Energy
- 628 Intake, Cardiometabolic Risk Parameters, Cancer, and Depression: A Systematic Review with
- 629 Meta-Analysis of Observational Studies. Advances in nutrition (Bethesda, Md). 2022;13:269-

630 281.

- 631 36. Tan X, Ciuculete DM, Schiöth HB and Benedict C. Associations between chronotype,
- MTNR1B genotype and risk of type 2 diabetes in UK Biobank. *Journal of internal medicine*.
  2020;287:189-196.
- 634 37. Knutson KL and von Schantz M. Associations between chronotype, morbidity and
  635 mortality in the UK Biobank cohort. *Chronobiology international*. 2018;35:1045-1053.
- 636 38. Lo EH and Faraci FM. Circadian Mechanisms in Cardiovascular and Cerebrovascular
- 637 Disease. *Circulation research*. 2024;134:615-617.
- 638 39. Zeng Q, Oliva VM, Moro MÁ and Scheiermann C. Circadian Effects on Vascular
- 639 Immunopathologies. *Circulation research*. 2024;134:791-809.

- 640 40. Sartor F, Ferrero-Bordera B, Haspel J, Sperandio M, Holloway PM and Merrow M.
- 641 Circadian Clock and Hypoxia. *Circulation research*. 2024;134:618-634.
- 41. Lal H, Verma SK, Wang Y, Xie M and Young ME. Circadian Rhythms in Cardiovascular
- 643 Metabolism. *Circulation research*. 2024;134:635-658.
- 42. Couch CA, Ament Z, Patki A, Kijpaisalratana N, Bhave V, Jones AC, Armstrong ND,
- 645 Cushman M, Kimberly WT and Irvin MR. Sex-Associated Metabolites and Incident Stroke,
- 646 Incident Coronary Heart Disease, Hypertension, and Chronic Kidney Disease in the
- 647 REGARDS Cohort. J Am Heart Assoc. 2024;13:e032643.
- 43. Yoshimoto S, Mitsuyama E, Yoshida K, Odamaki T and Xiao JZ. Enriched metabolites
- that potentially promote age-associated diseases in subjects with an elderly-type gut
   microbiota. *Gut microbes.* 2021;13:1-11.
- 44. Roenneberg T, Allebrandt KV, Merrow M and Vetter C. Social jetlag and obesity. Current
- 652 *biology : CB*. 2012;22:939-43.
- 45. Gao Z, Liu W, McDonough DJ, Zeng N and Lee JE. The Dilemma of Analyzing Physical
- 654 Activity and Sedentary Behavior with Wrist Accelerometer Data: Challenges and 655 Opportunities. *Journal of clinical medicine*. 2021;10.
- 46. Chase JD, Busa MA, Staudenmayer JW and Sirard JR. Sleep Measurement Using Wrist-
- Worn Accelerometer Data Compared with Polysomnography. *Sensors (Basel, Switzerland)*.
  2022;22.
- 47. Fairclough SJ, Noonan R, Rowlands AV, Van Hees V, Knowles Z and Boddy LM. Wear
- 660 Compliance and Activity in Children Wearing Wrist- and Hip-Mounted Accelerometers.
- 661 *Medicine and science in sports and exercise*. 2016;48:245-53.

- 48. Kennaway DJ. The dim light melatonin onset across ages, methodologies, and sex and
- 663 its relationship with morningness/eveningness. *Sleep.* 2023;46.
- 664 49. Strain T, Wijndaele K, Dempsey PC, Sharp SJ, Pearce M, Jeon J, Lindsay T, Wareham
- 665 N and Brage S. Wearable-device-measured physical activity and future health risk. Nature
- 666 *medicine*. 2020;26:1385-1391.

	Circadian misalignment <sup>b</sup>		
	Advanced group (N=12358)	Intermediate group (N=36464)	Delayed group (N=12143)
Basic information and lifestyle factors			
Women (%)	7088 (57.4)	22449 (61.6)	7466 (61.5)
Urban area (%)	10141 (82.9)	30038 (83.1)	10283 (85.6)
Age at baseline (years)	54.4 (8.2)	56.1 (7.8)	57.5 (7.2)
Townsend deprivation index <sup>c</sup>	-1.7 (2.8)	-1.9 (2.7)	-1.5 (2.9)
Level of education (%)			
College or University degree	5522 (44.7)	17084 (46.9)	5231 (43.1)
A levels/AS levels or Equivalent	1674 (13.6)	4837 (13.3)	1595 (13.1)
O levels/GCSEs or Equivalent	2504 (20.3)	7343 (20.1)	2448 (20.2)
None of the above	2658 (21.5)	7200 (19.8)	2869 (23.6)
White British (%)	11956 (96.8)	35551 (97.5)	11667 (96.1)
Family history of diabetes (%)	2367 (19.2)	7019 (19.3)	2358 (19.4)
Family history of cardiovascular diseases (%)	6726 (54.,4)	20796 (57.0)	7196 (59.3)
On-paid work (%)	8331 (67.4)	22289 (61.1)	6361 (52.4)
Drinking status (%)			
Never drinker	372 (3.0)	952 (2.6)	371 (3.1)
Ever drinker	365 (3.0)	817 (2.2)	382 (3.2)
Current drinker	11621 (94.0)	34695 (95.2)	11390 (93.8)
Smoking status (%)			
Never smoker	7212 (58.4)	21802 (59.8)	6627 (54.6)
Ever smoker	4302 (34.8)	12619 (34.6)	4427 (36.5)
Current smoker	844 (6.8)	2043 (5.6)	1089 (9.0)
Daily average coffee intake (cups)	2.0 (2.0)	1.9 (1.9)	2.0 (2.0)
Daily average tea intake (cups)	3.2 (2.7)	3.3 (2.6)	3.4 (2.8)
Mediterranean dietary score (points)	2.9 (1.4)	2.9 (1.4)	2.9 (1.4)
Daily average time on moderate to vigorous			
physical activity per day <sup>d</sup> (min)	117.0 (53.2)	115.4 (50.5)	104.9 (50.1)
Daily average ambivalent Light exposure <sup>e</sup> (lux)	781.2 (161.6)	803.7 (149.0)	788.3 (154.7)
Daily average ambivalent noise' (dB)	51.2 (4.2)	51.1 (4.1)	51.2 (4.3)
Circadian and sleep			
Chronotype			
Early	2960 (24.0)	9262 (25.4)	3449 (28.4)
Intermediate early	4702 (38.1)	14507 (39.8)	3936 (32.4)
Intermediate late	3485 (28.2)	9944 (27.3)	3334 (27.5)
Late	1211 (9.8)	2751 (7.5)	1424 (11.7)
Weekly average midsleep <sup>g</sup> (hh:mm)	02:06 (00:48)	03:18 (00:30)	04:24 (00:48)
Midsleep on weekdays (hh:mm)	02:06 (00:54)	03:18 (00:30)	04:36 (00:54)
Midsleep on weekends (hh:mm)	02:12 (01:24)	03:24 (00:48)	04:42 (01:06)
Social jetlag <sup>h</sup> (hours)	0.1 (1.6)	0.2 (0.8)	0.1 (1.2)
			35

# Table1. Baseline characteristics of 60965 study participants from UK Biobank according to circadian misalignment<sup>a</sup>

Residuals of midsleep on chronotype <sup>b</sup>	-1.2 (0.7)	0.0 (0.4)	1.3 (0.6)
Healthy sleep quality score (points) <sup>i</sup>	3.2 (0.9)	3.3 (0.9)	3.1 (0.9)

<sup>a</sup> Values are mean and standard deviation or number and percentage.

<sup>b</sup> Circadian misalignment was calculated by the residuals of midsleep on chronotype, while the negative or positive value of circadian misalignment indicated an advanced or delayed real sleep-wake cycle comparing to circadian preference. The first quintile of residuals of midsleep on chronotype was defined as the advanced group, demonstrating an advanced sleep-wake cycle relative to their circadian preference. Conversely, the fifth quintile was defined as the delayed group, which indicated a delayed sleep-wake cycle in comparison to circadian preference. The remaining quintiles (Q2, Q3, Q4) combined together were defined as the intermediate group.

<sup>c</sup> Townsend deprivation index is calculated based on the preceding national census output areas. Each participant is assigned a score corresponding to the output area in which their postcode is located. Higher value indicated a poorer socioeconomic status.

<sup>d</sup> Accelerometer-derived time on moderate or vigorous activity per day, weighted by weekends and weekdays based on R package GGIR<sup>19</sup>.

<sup>e</sup> Accelerometer-derived mean waking hours' light exposure per day based on R package GGIR<sup>19</sup>.

<sup>f</sup> Day-evening-night equivalent noise level: A-weighted local environment annual average noise level measured over the 24-hour period.

<sup>g</sup> Accelerometer-derived time on average midpoint between sleep onset and sleep end, derived and weighted by weekends and weekdays based on R package GGIR<sup>19</sup>.

<sup>h</sup> Difference between accelerometer-derived time of midsleep on weekends and workdays, derived and weighted by weekends and weekdays based on R package GGIR<sup>19</sup>.

<sup>1</sup> The healthy sleep quality score is calculated by the sum of five components (chronotype, 24-hour sleep duration, insomnia, snoring, and daytime sleepiness) from a touchscreen sleep questionnaire. It ranges from 0-5, with a higher score indicating a better sleep quality.

	Incidence density (events/person-years)	Model 1 <sup>b</sup>	Model 2 <sup>c</sup>	Model 3 <sup>d</sup>
Type 2 diabetes				
Q1	300/94667	1.30 (1.10, 1.54)	1.26 (1.07, 1.50)	1.22 (1.03, 1.45)
Q2	244/94046	1.01 (0.84, 1.20)	1.01 (0.85, 1.21)	1.02 (0.85, 1.22)
Q3	243/94917	Reference	Reference	Reference
Q4	310/96293	1.19 (1.01, 1.41)	1.18 (1.00, 1.39)	1.17 (0.99, 1.38)
Q5	429/95528	1.59 (1.36, 1.87)	1.51 (1.29, 1.77)	1.39 (1.18, 1.62)
Coronary heart diseas	se			
Q1	423/92171	1.14 (1.00, 1.31)	1.13 (0.99, 1.30)	1.12 (0.98, 1.29)
Q2	364/91674	0.98 (0.85, 1.13)	0.98 (0.85, 1.13)	0.98 (0.85, 1.13)
Q3	391/92489	Reference	Reference	Reference
Q4	482/93398	1.16 (1.02, 1.33)	1.15 (1.01, 1.32)	1.15 (1.01, 1.31)
Q5	526/92501	1.25 (1.09, 1.42)	1.22 (1.07, 1.39)	1.16 (1.02, 1.33)
Stroke				
Q1	130/94424	1.06 (0.83, 1.35)	1.06 (0.83, 1.35)	1.04 (0.82, 1.33)
Q2	114/93768	0.91 (0.71, 1.17)	0.92 (0.71, 1.18)	0.92 (0.72, 1.19)
Q3	133/94636	Reference	Reference	Reference
Q4	160/95895	1.11 (0.89, 1.40)	1.11 (0.88, 1.39)	1.10 (0.88, 1.39)
Q5	147/95220	0.99 (0.78, 1.25)	0.97 (0.76, 1.22)	0.91 (0.72, 1.16)
Cardiometabolic even	ıts			
Q1	780/91496	1.16 (1.05, 1.29)	1.15 (1.03, 1.27)	1.12 (1.02, 1.25)
Q2	675/91071	0.98 (0.88, 1.09)	0.98 (0.88, 1.09)	0.98 (0.89, 1.09)
Q3	714/91852	Reference	Reference	Reference
Q4	884/92598	1.17 (1.06, 1.29)	1.16 (1.05, 1.28)	1.15 (1.04, 1.27)
Q5	1031/91626	1.33 (1.21, 1.46)	1.29 (1.17, 1.41)	1.21 (1.10, 1.33)

Table2. Associations between quintiles of circadian misalignment and cardiometabolic outcomes by Cox proportionate hazard models<sup>a</sup>

<sup>a</sup> Circadian misalignment was categorized by quintiles of residuals of midsleep on chronotype, while the negative or positive value of circadian misalignment indicated an advanced or delayed real sleep-wake cycle comparing to circadian preference. Values are hazard ratio and 95% confidence intervals.

<sup>b</sup>Adjusted for age, sex, and ethnic group;

<sup>c</sup> Further adjusted for region, social economic status, employment, education, and ambient noise level;

<sup>d</sup> Further adjusted for smoking status, drinking status, tea consumption, coffee consumption, moderate to vigorous physic activity, and healthy sleep quality score (calculated from chronotype, insomnia, snore, daytime sleepiness, and sleep duration).

D. C. C. L. C. K. C.	Total effect		Natural direct effect		Natural indirect effect		Proportion mediated	
Potential mediators	HR (95%CI)	Р	HR (95%CI)	Р	HR (95%CI)	Р	% (95%CI)	Р
T2D								
Liver function								
Alanine aminotransferase (U/L)	1.15 (1.08, 1.21)	<.001	1.14 (1.07, 1.20)	<.001	1.01 (1.00, 1.01)	<.001	6.2 (3.1, 12.6)	<.001
Alkaline phosphatase (U/L)	1.16 (1.08, 1.23)	<.001	1.15 (1.08, 1.22)	<.001	1.01 (1.00, 1.01)	<.001	4.6 (2.4, 8.4)	<.001
Aspartate aminotransferase (U/L)	1.15 (1.08, 1.23)	<.001	1.15 (1.08, 1.22)	<.001	1.00 (1.00, 1.01)	0.02	3.0 (0.8, 6.0)	0.02
Gamma glutamyl transferase (U/L)	1.15 (1.08, 1.21)	<.001	1.13 (1.06, 1.19)	<.001	1.01 (1.01, 1.02)	<.001	9.1 (5.3, 18.7)	<.001
Total bilirubin (μmol/L)	1.16 (1.09, 1.22)	<.001	1.16 (1.09, 1.21)	<.001	1.00 (1.00, 1.01)	<.001	2.4 (1.1, 5.0)	0.001
Overall	1.15 (1.09, 1.23)	<.001	1.14 (1.07, 1.21)	<.001	1.02 (1.01, 1.02)	<.001	12.3 (7.1, 20.0)	<.001
Lipid and glucose metabolism								
HDL-C (mmol/L)	1.17 (1.09, 1.23)	<.001	1.15 (1.08, 1.21)	<.001	1.01 (1.01, 1.02)	<.001	10.0 (6.1, 18.5)	<.001
Triglycerides (mmol/L)	1.15 (1.09, 1.22)	<.001	1.14 (1.07, 1.20)	<.001	1.01 (1.01, 1.02)	<.001	9.8 (4.8, 20.1)	<.001
Apolipoprotein A (g/L)	1.16 (1.09, 1.23)	<.001	1.15 (1.08, 1.22)	<.001	1.01 (1.00, 1.01)	<.001	5.9 (3.1, 11.0)	0.001
HbA1c (%)	1.15 (1.07, 1.22)	<.001	1.12 (1.05, 1.19)	<.001	1.02 (1.01, 1.04)	<.001	16.9 (5.2, 34.0)	<.001
Overall	1.15 (1.09, 1.24)	<.001	1.11 (1.05, 1.20)	<.001	1.03 (1.02, 1.05)	<.001	24.5 (12.3, 41.1)	<.001
Inflammatory biomarkers								
C-reactive protein (mg/L)	1.16 (1.10, 1.22)	<.001	1.14 (1.07, 1.19)	<.001	1.02 (1.02, 1.03)	<.001	15.5 (11.0, 28.1)	<.001
White blood cell count $(x10^9/L)$	1.16 (1.09, 1.22)	<.001	1.15 (1.07, 1.20)	<.001	1.01 (1.01, 1.02)	<.001	8.8 (6.2, 17.4)	<.001
Overall	1.16 (1.09, 1.23)	<.001	1.13 (1.06, 1.20)	<.001	1.03 (1.02, 1.04)	<.001	20.0 (13.9, 37.0)	<.001
Anthropometric indices								
Systolic blood pressure (mmHg)	1.16 (1.09, 1.23)	<.001	1.15 (1.08, 1.22)	0.02	1.01 (1.00, 1.01)	0.02	3.7 (1.1, 8.3)	0.002
Body mass index (kg/m <sup>2</sup> )	1.15 (1.07, 1.22)	<.001	1.10 (1.03, 1.16)	0.02	1.05 (1.04, 1.06)	<.001	35.2 (23.9, 62.2)	<.001

Table 3. Multiple mediation models of potential mediators in the association between circadian misalignment and T2D as well as CHD<sup>a</sup>

Waist-hip ratio	1.16 (1.08, 1.23)	<.001	1.11 (1.04, 1.18)	<.001	1.04 (1.03, 1.05)	<.001	27.1 (17.7, 47.7)	<.001
Overall	1.15 (1.08, 1.23)	<.001	1.08 (1.01, 1.15)	0.02	1.06 (1.05, 1.07)	<.001	44.6 (31.7, 81.8)	<.001
СНД								
Liver function								
Alanine aminotransferase (U/L)	1.09 (1.03, 1.16)	<.001	1.09 (1.03, 1.15)	<.001	1.00 (1.00, 1.00)	<.001	1.5 (0.3, 4.2)	<.001
Alkaline phosphatase (U/L)	1.09 (1.03, 1.16)	0.02	1.09 (1.03, 1.15)	0.02	1.00 (1.00, 1.01)	<.001	4.4 (1.8, 12.7)	0.02
Gamma glutamyl transferase (U/L)	1.09 (1.03, 1.16)	<.001	1.09 (1.03, 1.15)	<.001	1.00 (1.00, 1.00)	<.001	3.4 (1.5, 11.0)	<.001
Albumin (g/L)	1.10 (1.02, 1.16)	0.04	1.09 (1.02, 1.16)	0.04	1.00 (1.00, 1.00)	<.001	2.1 (0.5, 6.9)	0.04
Overall	1.09 (1.04, 1.15)	<.001	1.08 (1.03, 1.14)	<.001	1.01 (1.01, 1.01)	<.001	8.8 (5.0, 22.6)	<.001
Lipid and glucose metabolism								
HDL-C (mmol/L)	1.10 (1.04, 1.16)	0.02	1.09 (1.03, 1.15)	0.02	1.01 (1.00, 1.01)	<.001	6.2 (2.7, 14.8)	0.02
Triglycerides (mmol/L)	1.10 (1.04, 1.16)	0.02	1.09 (1.03, 1.16)	0.02	1.01 (1.00, 1.01)	<.001	4.0 (1.6, 9.9)	0.02
Apolipoprotein A (g/L)	1.10 (1.04, 1.16)	0.02	1.09 (1.03, 1.16)	0.02	1.01 (1.00, 1.01)	<.001	4.5 (1.7, 13.1)	0.02
HbA1c (%)	1.09 (1.03, 1.16)	0.02	1.09 (1.03, 1.15)	0.02	1.00 (1.00, 1.00)	<.001	2.8 (0.4, 7.5)	0.02
Overall	1.09 (1.04, 1.17)	<.001	1.09 (1.03, 1.16)	<.001	1.01 (1.00, 1.01)	<.001	9.1 (4.5, 20.6)	<.001
Inflammatory biomarkers								
C-reactive protein (mg/L)	1.10 (1.04, 1.16)	<.001	1.09 (1.03, 1.15)	<.001	1.01 (1.01, 1.01)	<.001	10.7 (6.2, 27.1)	<.001
White blood cell count ( $x10^9/L$ )	1.09 (1.04, 1.16)	<.001	1.09 (1.03, 1.15)	<.001	1.01 (1.00, 1.01)	<.001	5.8 (2.7, 14.5)	<.001
Overall	1.09 (1.03, 1.16)	<.001	1.08 (1.02, 1.14)	<.001	1.01 (1.01, 1.02)	<.001	13.7 (7.1, 38.5)	<.001
Anthropometric indices								
Systolic blood pressure (mmHg)	1.10 (1.04, 1.16)	0.02	1.09 (1.03, 1.16)	0.02	1.00 (1.00, 1.01)	0.02	4.6 (0.7, 12.7)	0.04
Body mass index (kg/m <sup>2</sup> )	1.09 (1.03, 1.16)	0.02	1.08 (1.02, 1.14)	0.04	1.01 (1.01, 1.02)	<.001	16.8 (9.3, 44.2)	0.02
Waist-hip ratio	1.09 (1.03, 1.16)	0.02	1.08 (1.02, 1.15)	0.04	1.01 (1.01, 1.01)	<.001	11.9 (6.0, 29.7)	0.02
Overall	1.09 (1.03, 1.15)	0.02	1.08 (1.01, 1.13)	0.02	1.02 (1.01, 1.02)	<.001	20.3 (11.5, 63.7)	0.02

<sup>a</sup> Models were adjusted for age, sex, region, ethnic group, social economic status, employment, education, daily average noise level, smoking status, drinking status, tea consumption, coffee consumption, moderate to vigorous physic activity, and healthy sleep quality score. The levels of biomarkers were nature log transformed. Mediation analyses were conducted by R package CMAverse.

Abbreviation: T2D, type 2 diabetes, CHD, coronary heart diseases, HR (95%CI), hazard ratio (95% confidence limit).

Figure 1. Flow chart of the study



Diseases	Chronotype	HR1 (95% CI)	Midsleep	HR2 (95% CI)	Diseases*	Difference	HR3 (95% CI)	Residual	HR4 (95% CI)
T2D					T2D				
Early		1.19 (1.06, 1.34)		1.05 (0.93, 1.20)	Advanced		1.04 (0.90, 1.20)		1 <b>.1</b> 5 (1.0 <mark>1</mark> , 1.31)
Intermediate	•	Reference	•	Reference	Intermediate	•	Reference	•	Reference
Late		1.02 (0.86, 1.22)		1.21 (1.07, 1.36)	Delayed		1.19 (1.06, 1.33)		1.30 (1.15, 1.47)
CHD					CHD				
Early		1.02 (0.93, 1.13)		0.98 (0.88, 1.09)	Advanced		1.05 (0.93, 1.18)	<b>↓</b> ■−	1.07 (0.96, 1.20)
Intermediate	•	Reference	•	Reference	Intermediate	1 <b>†</b> 1	Reference	1	Reference
Late		1.05 (0.90, 1.22)		1.07 (0.96, 1.18)	Delayed		1.06 (0.97, 1.17)		1.11 (1.00, 1.23)
Stroke					Stroke				
Early		0.96 (0.80, 1.14)		1.03 (0.85, 1.25)	Advanced		1.03 (0.82, 1.28)		1.03 (0.85, 1.26)
Intermediate	• • •	Reference	•	Reference	Intermediate	1 <b>†</b> 1	Reference	1 <b>†</b> 1	Reference
Late		0.75 (0.55, 1.01)		1.08 (0.90, 1.29)	Delayed		1.02 (0.87, 1.21)		0.90 (0.74, 1.09)
CMD					CMD				
Early	-	1.07 (0.99, 1.15)	+	1.00 (0.92, 1.08)	Advanced	-	1.03 (0.94, 1.13)		1.07 (0.99, 1.16)
Intermediate	•	Reference	•	Reference	Intermediate	•	Reference	•	Reference
Late	-	1.00 (0.90, 1.12)	-	1.13 (1.04, 1.21)	Delayed	-	1.10 (1.03, 1.17)	-	1.15 (1.07, 1.24)
	0.7 1 1.3		0.7 1 1.3			0.7 1 1.3		0.7 1 1.3	

Figure 2 The risk of circadian preference, midsleep, and circadian misalignment on cardiometabolic outcomes

Chronotype indicated circadian preference of participants. Difference was calculated by subtracting chronotype group (early, intermediate, and late) from midsleep group (early, intermediate, and late), while Residual was calculated by the residuals of midsleep (continuous variable) on chronotype. Models were adjusted for age, sex, region, social economic status, employment, education, ethnic group, daily average noise level, smoking status, tea consumption, coffee

consumption, moderate to vigorous physic activity, and healthy sleep quality score (chronotype was omitted from healthy sleep quality score when analyzing the association between chronotype and cardiometabolic outcomes). Chronotype and midsleep were also mutually adjusted.

\*The category of circadian difference and residuals are different from chronotype and midsleep. Participants can be categorized into early, intermediate, and late group by chronotype and midsleep, whereas they were categorized into advanced, intermediate, and delayed sleep-wake cycle group compare to their chronotype. Abbreviation: T2D, Type 2 diabetes; CHD, coronary heart diseases; CMD, cardiometabolic diseases (incident of any of T2D, CHD, and Stroke), HR (95%CI), hazard ratio and 95% confidence limit.